Clinical evaluation comparing the efficacy of aquacel ag hydrofiber dressing versus petrolatum gauze with antibiotic ointment in partial-thickness burns in a pediatric burn center.
We conducted this Institutional Review Board-approved retrospective study to compare Aquacel Ag Hydrofiber dressing (Aquacel Ag) to a standard dressing for the treatment of partial thickness burns in children. We used the St. Christopher's Hospital burn center registry to identify 20 pediatric patients who had sustained partial thickness burns over a 10-month period. Ten of these patients had been treated with Aquacel Ag Hydrofiber dressing and 10 were treated with conventional Xeroflo gauze with Bacitracin Zinc ointment, the institutional standard of care for nonoperative partial-thickness burn wounds. Inclusion criteria included anyone with partial-thickness burns below the age of 18 years and in excellent baseline health. Exclusion criteria included inhalation injury, presence of full-thickness burns necessitating surgical debridement, cellulitic, or infected wounds, and percentage total body surface area involvement greater than 40%. Outcomes measured for the Aquacel Ag versus the Xeroflo gauze with Bacitracin Zinc ointment group included hospital length of stay (2.4 vs. 9.6 days), total number of in-house dressing changes (2.7 vs. 17.1), pain on a 10-point scale associated with dressing changes (6.4 vs. 8.2), total number of intravenous narcotic administrations (2.3 vs. 14.4), nursing time adjusted for percentage total body surface area (1.9 vs. 3.5 min), time to wound reepithelialization (10.3 vs. 16.3 days), and patient primary caregiver satisfaction score using a 4-point scale--with four delineating maximum satisfaction (3.8 vs. 1.8). Aquacel Ag proved to be a safe and effective means of treating partial thickness burns with a significant reduction in nursing time and patient pain involved with dressing changes.
Saba
Salim Charles
SC
Department of Surgery, Drexel University College of Medicine, Philadelphia, Pennsylvania 19102, USA.
Tsai
Roger
R
Glat
Paul
P
D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001414:Bacitracin / Q000627:therapeutic use*; D002053:Burn Units; D002056:Burns / Q000628:therapy*; D002266:Carboxymethylcellulose Sodium / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D009779:Occlusive Dressings; D009824:Ointments / Q000627:therapeutic use; D010147:Pain Measurement; D010577:Petrolatum / Q000627:therapeutic use; D012042:Registries; D012189:Retrospective Studies; D018709:Statistics, Nonparametric; D013530:Surgical Wound Infection / Q000517:prevention & control; D014945:Wound Healing / Q000187:drug effects*
D000900:Anti-Bacterial Agents; D009824:Ointments; D001414:Bacitracin; D010577:Petrolatum; D002266:Carboxymethylcellulose Sodium